(MedPage Today) — Adding a dual GLP-1/GIP receptor agonist to the psoriasis drug ixekizumab (Taltz) significantly improved outcomes in adults with difficult-to-treat plaque psoriasis due to overweight or obesity, the open-label TOGETHER-PsO trial…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
